The Finnish pioneer in identifying and compiling relevant data for pharmaceutical research projects broadens its in-house expertise to also cover Swedish healthcare registries, to provide customers access to an even larger trove of high-quality healthcare data.
Medaffcon has added Swedish healthcare registries to its capabilities as it continues to pursue growth and facilitate data utilisation by providing pharmaceutical companies access to rich and relevant healthcare data.
CEO Jarmo Hahl says the expansion aligns with the needs of both the company and its customers.
It allows the company to continue growing and increase the amount of high-quality digital healthcare data it can sift through to collate datasets and analyses that satisfy the specific needs of each pharmaceutical research project.
“The Nordic market is growing, and you have to be there to succeed,” he states. “Sweden is also the main market for many pharmaceutical companies.”
“Customers can be confident that they’ll have access to our familiar and solutions-oriented model of operation also in Sweden.”
The primary impetus for the expansion, however, was the desire of many customers to combine healthcare data from registries across the Nordics – and accomplish this as flexibly and cost-efficiently as possible.
“Medaffcon wants to respond to that demand and offer in-house expertise in Sweden. Customers can be confident that they’ll have access to our familiar and solutions-oriented model of operation also in Sweden,” promises Hahl.
This bodes well also – and most importantly – for patients. By drawing from a larger pool of healthcare data, pharmaceutical companies can target, develop and launch their products more precisely for certain diseases and patient groups, potentially resulting in safer and more personalised pharmacotherapies.
“As medications today are introduced for increasingly specific diseases and populations, our capacity to plan and execute studies is better when we can combine data from various countries,” explains Dr. Mariann Lassenius, the real-world evidence lead at Medaffcon.
Moving data from Sweden to Finland can be done securely, and the data can be combined for valuable analyses without regulatory restrictions, she points out.
Medaffcon has recruited Dr. Johanna Simin, a clinical epidemiologist with a PhD from the Karolinska Institute in Stockholm, as its lead real-world epidemiologist in Sweden. Dr. Simin has used Swedish national and disease-specific health and administrative data registries in numerous large-scale research projects for the past decade, building not only her expertise of healthcare data but also an extensive network of contacts in Sweden.
Sweden’s high-quality healthcare system, she tells, offers comprehensive longitudinal patient-oriented data registries, valid data linkage possibilities and simply a vast amount of readily available data.
“The climate is also fairly supportive of research and innovation,” she adds. “Once you satisfy with the regulatory requirements, the data become available.”
“The Nordics, with their exceptional data sources and infrastructure, are clear forerunners in the real-world data and evidence landscape. I’m thrilled that we can now provide state-of-the-art real-world evidence solutions in both Finland and Sweden, to Medaffcon’s new and present customers,” says Dr. Simin.
“Sweden’s high-quality healthcare system offers a vast amount of readily available data.”
By leveraging its access and understanding of the high-quality healthcare services, massive digital data repositories and research-supportive operating environment in the Nordics, Medaffcon is uniquely positioned to be a reliable and valuable partner for organisations eager to utilise healthcare data for research and product development.
The lymphoma research project has proven to be an exceptionally versatile source of new knowledge. The project includes at least two doctoral researchers, and its results are expected to generate well over ten scientific articles.
5th Nordic RWE and AI conference is organized by University of Helsinki and Åbo Akademi University. Register to the event here!
Despite its high-risk nature and availability of kidney treatments, chronic kidney disease (CKD) often goes undiagnosed. This especially concerns patients without type 2 diabetes (T2D), who represent the majority of CKD patients. This finding comes from a recent registry study published in Nephrology Dialysis Transplantation (NDT).
Sr. Scientific Advisor
RWE Lead
PhD
+358 50 345 2393
mariann.lassenius@medaffcon.fi
Mariann joined Medaffcon’s team in 2016 after finishing her PhD. The transition to real world evidence (RWE) research was a natural continuum to her previous research career. Through RWE studies, she has had the privilege to gain a broad insight into working with different stakeholders within the healthcare field. The vast proportion of her days goes towards interacting with clients, planning and performing RWE studies, and supporting Medaffcon’s RWE team. Subjects that keep her work interesting are the vast variability of customers and projects, problem-solving, and interacting with people.
“The number of RWE studies has increased since stakeholders within the healthcare industry have an increasing demand for knowledge-based decision making tools that need to be fulfilled. The future, therefore, has an ever-increasing emphasis on RWE”.